<DOC>
	<DOCNO>NCT01193257</DOCNO>
	<brief_summary>This randomize , double-blind , multicenter , phase 3 study evaluate orteronel plus prednisone compare placebo plus prednisone men metastatic , castration-resistant prostate cancer ( mCRPC ) progress follow Docetaxel-based therapy</brief_summary>
	<brief_title>Study Comparing Orteronel Plus Prednisone Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion : Voluntary write consent Male patient 18 year old Histologically cytologically confirm diagnosis prostate adenocarcinoma Radiographdocumented metastatic disease Progressive disease Prior surgical castration concurrent use agent medical castration Have progressive disease follow 1 2 regimen cytotoxic chemotherapy , 1 must include docetaxel . Must receive ≥ 360 mg/m2 docetaxel within 6month period . Patients clearly intolerant docetaxel develop progressive disease receive ≥ 360 mg/m2 also eligible receive least 225 mg/m2 docetaxel within 6month period meet study entry criterion . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Even surgically sterilize , patient must Practice effective barrier contraception entire study treatment period 4 month last dose study drug , OR Abstain heterosexual intercourse Meet screen laboratory value specify protocol Stable medical condition Life expectancy 6 month Patients 2 prior chemotherapy treatment eligible participate Patients meet follow exclusion criterion enrol study : Known hypersensitivity orteronel , prednisone gonadotropinreleasing hormone ( GnRH ) analogue Received prior therapy orteronel , aminoglutethimide , ketoconazole abiraterone Any therapy prostate cancer , except GnRH analogue therapy , must discontinue 2 week first dose study drug Radioisotope therapy external beam radiation therapy within 4 week first dose study drug Documented central nervous system metastases Treatment investigational compound within 30 day prior ro first dose study drug ( Patients longterm followup follow active treatment trial eligible ) Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Uncontrolled cardiovascular condition specify study protocol Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Unwilling unable comply protocol Known gastrointestinal disease procedure could interfere oral absorption tolerance orteronel Uncontrolled nausea , vomit , diarrhea despite appropriate medical therapy Patients whose prostate cancer confine prostrate bed immediate adjacent tissue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>